Floatz logo

Pembrolizumab

Fallopian Tube Carcinoma

Roswell Park Cancer Institutemonoclonal_antibodyPhase 2Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
81/ 100

Competitive context

70 Active assets in the Fallopian Tube Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Women's Hospital School Of Medicine Zhejiang University
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Phase 3BB
Cyclophosphamide
Mayo Clinic
Phase 2BB
TAMOXIFEN
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3BB
Olaparib
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →